SG11201910172VA - Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors - Google Patents
Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitorsInfo
- Publication number
- SG11201910172VA SG11201910172VA SG11201910172VA SG11201910172VA SG 11201910172V A SG11201910172V A SG 11201910172VA SG 11201910172V A SG11201910172V A SG 11201910172VA SG 11201910172V A SG11201910172V A SG 11201910172VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maharashtra
- oxidase inhibitors
- nadph oxidase
- compounds
- Prior art date
Links
- 108010002998 NADPH Oxidases Proteins 0.000 title abstract 4
- 102000004722 NADPH Oxidases Human genes 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 125000002618 bicyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 102100021217 Dual oxidase 2 Human genes 0.000 abstract 1
- 101000968308 Homo sapiens Dual oxidase 1 Proteins 0.000 abstract 1
- 101000968305 Homo sapiens Dual oxidase 2 Proteins 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721015787 | 2017-05-04 | ||
| PCT/IB2018/053121 WO2018203298A1 (en) | 2017-05-04 | 2018-05-04 | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910172VA true SG11201910172VA (en) | 2019-11-28 |
Family
ID=62245373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910172V SG11201910172VA (en) | 2017-05-04 | 2018-05-04 | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200247800A1 (pt) |
| EP (1) | EP3619209A1 (pt) |
| JP (1) | JP2020518624A (pt) |
| KR (1) | KR20200013665A (pt) |
| CN (1) | CN110914263A (pt) |
| AU (1) | AU2018262528A1 (pt) |
| BR (1) | BR112019023109A2 (pt) |
| CA (1) | CA3062185A1 (pt) |
| CL (1) | CL2019003107A1 (pt) |
| CO (1) | CO2019013655A2 (pt) |
| EA (1) | EA201992343A1 (pt) |
| MX (1) | MX2019013148A (pt) |
| PE (1) | PE20191789A1 (pt) |
| PH (1) | PH12019502462A1 (pt) |
| SG (1) | SG11201910172VA (pt) |
| WO (1) | WO2018203298A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005914A2 (pt) | 2018-10-01 | 2021-06-29 | Genzyme Corporation | derivados de tieno[3,2-b]piridina como inibidores de udp glicosiltransferase e métodos de uso |
| CN115215767B (zh) * | 2021-04-16 | 2023-09-12 | 帕潘纳(北京)科技有限公司 | 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法 |
| CN113292496B (zh) * | 2021-05-17 | 2023-03-10 | 安徽联创生物医药股份有限公司 | 一种劳拉替尼中间体的合成方法 |
| WO2023217764A1 (en) | 2022-05-09 | 2023-11-16 | Calliditas Therapeutics Suisse Sa | Nox inhibitors for use in the treatment of alport syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2004089412A1 (ja) * | 2003-04-08 | 2006-07-06 | 三菱ウェルファーマ株式会社 | 特異的ｎａｄ（ｐ）ｈオキシダーゼ抑制剤 |
| JP2007133750A (ja) * | 2005-11-11 | 2007-05-31 | Canon Inc | 情報処理方法及び情報処理装置 |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| FR2929276B1 (fr) * | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| GB201104600D0 (en) * | 2011-03-18 | 2011-05-04 | Pronoxis Ab | New compounds and medical uses |
| JP7105691B2 (ja) * | 2015-11-25 | 2022-07-25 | イーフェクター セラピューティクス， インコーポレイテッド | Ｅｉｆ４ａ－阻害化合物およびそれに関連する方法 |
-
2018
- 2018-05-04 EP EP18727437.8A patent/EP3619209A1/en not_active Withdrawn
- 2018-05-04 EA EA201992343A patent/EA201992343A1/ru unknown
- 2018-05-04 CN CN201880044473.8A patent/CN110914263A/zh active Pending
- 2018-05-04 US US16/610,351 patent/US20200247800A1/en not_active Abandoned
- 2018-05-04 JP JP2019560286A patent/JP2020518624A/ja active Pending
- 2018-05-04 BR BR112019023109-9A patent/BR112019023109A2/pt not_active Application Discontinuation
- 2018-05-04 MX MX2019013148A patent/MX2019013148A/es unknown
- 2018-05-04 KR KR1020197035127A patent/KR20200013665A/ko unknown
- 2018-05-04 SG SG11201910172V patent/SG11201910172VA/en unknown
- 2018-05-04 AU AU2018262528A patent/AU2018262528A1/en not_active Abandoned
- 2018-05-04 PE PE2019002276A patent/PE20191789A1/es unknown
- 2018-05-04 CA CA3062185A patent/CA3062185A1/en not_active Abandoned
- 2018-05-04 WO PCT/IB2018/053121 patent/WO2018203298A1/en unknown
-
2019
- 2019-10-29 CL CL2019003107A patent/CL2019003107A1/es unknown
- 2019-10-31 PH PH12019502462A patent/PH12019502462A1/en unknown
- 2019-12-03 CO CONC2019/0013655A patent/CO2019013655A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110914263A (zh) | 2020-03-24 |
| EP3619209A1 (en) | 2020-03-11 |
| EA201992343A1 (ru) | 2020-04-16 |
| AU2018262528A1 (en) | 2019-11-21 |
| MX2019013148A (es) | 2019-12-18 |
| CO2019013655A2 (es) | 2020-04-01 |
| PH12019502462A1 (en) | 2020-06-29 |
| US20200247800A1 (en) | 2020-08-06 |
| WO2018203298A1 (en) | 2018-11-08 |
| CA3062185A1 (en) | 2018-11-08 |
| JP2020518624A (ja) | 2020-06-25 |
| CL2019003107A1 (es) | 2020-03-13 |
| BR112019023109A2 (pt) | 2020-05-26 |
| KR20200013665A (ko) | 2020-02-07 |
| PE20191789A1 (es) | 2019-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201910172VA (en) | Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201808708RA (en) | Heterocyclic amides useful as protein modulators | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201808729WA (en) | Bet protein degraders | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201811549UA (en) | Boronic acid derivatives and therapeutic uses thereof | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201407115XA (en) | Carboxylic acid compounds | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201804223TA (en) | OCTAHYDROPYRROLO [3, 4-c] PYRROLE DERIVATIVES AND USES THEREOF | |
| SG11201806480UA (en) | Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof |